By proceeding, you agree to our Terms of Use and Privacy Policy.
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases.
16-18 March 2022
IO360°convenes stakeholders from the science and business communities to report on the latest data impacting IO to fight a wider range of cancers.
Event Ended
USA
Paid
New York
04-05 April 2022
The 10th annual Chief Medical Officer Summit 360° attracts the largest gathering of physicians in biotech to address the unique challenges associated with directing and managing R&D functions with limited resources, while raising capital and strategi
Boston
19-22 September 2022
Across 3 main conference days and 8 tracks, 200+ CAR and TCR experts will lead you and your peers in discussions from novel allogeneic approaches with enhanced safety considerations, the latest in vivo gene engineering techniques, and advances in CMC
12-13 July 2023
The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encourage
29-01 September 2023
The Vice President of Discovery and Translational Research at Deverra Therapeutics, Erika von Euw, highly recommends attending the upcoming CAR-TCR Summit if you work in cell therapy. Last year marked a significant milestone in the field of cell ther